Chunghwa Chemical Synthesis & Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Chunghwa Chemical Synthesis & Biotech CEO'su Chung-Hsin Huang, Apr2018 tarihinde atandı, in görev süresi 6.58 yıldır. şirketin hisselerinin 0.074% doğrudan sahiptir ve bu hisselerin değeri NT$ 2.21M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.6 yıl ve 4.8 yıldır.

Anahtar bilgiler

Chung-Hsin Huang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.6yrs
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	6.6yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

Why Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 22

Chunghwa Chemical Synthesis & Biotech (TWSE:1762) Has A Somewhat Strained Balance Sheet

Nov 14

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry

Aug 09

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80

Jul 12

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 04

A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Apr 01

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Mar 04

What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend

Jan 28

Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?

Jan 02

The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It

Dec 06

CEO

Chung-Hsin Huang

6.6yrs

Görev süresi

Mr. Chung-Hsin Huang serves as President & General Manager at Chunghwa Chemical Synthesis & Biotech Co., Ltd. Since April 1, 2018 and served as Director until May 2022. Mr. Huang had been Vice President of...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chung-Hsin Huang	President & GM	6.6yrs	Veri yok	0.074% NT$ 2.2m
Kuan-Chieh Wang	Manager of Finance Department & Head of Corporate Governance	6yrs	Veri yok	Veri yok
Jun-Jie Liao	Manager of Human Resource Office	6.8yrs	Veri yok	Veri yok
Chao-Sheng Hong	Chief Auditor	no data	Veri yok	Veri yok

6.6yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 1762 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kuo-Chiang Wang	Independent Director	14.4yrs	Veri yok	Veri yok
Chih-Hsien Chang	Independent Director	8.5yrs	Veri yok	Veri yok
Hou-Jie Wang	Director	4.8yrs	Veri yok	1.3% NT$ 38.6m
Yi-Zhen Xie Wang	Chairman of the Board	4yrs	Veri yok	3.17% NT$ 94.1m
Hou-Kai Wang	Vice-Chairman	less than a year	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 1762 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Chunghwa Chemical Synthesis & Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Elects Hou-Kai as Vice Chairman

Chunghwa Chemical Synthesis & Biotech Co., Ltd., Annual General Meeting, May 30, 2024

Insufficient new directors

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Appointment of Kuan Arthur¡G as Independent Director

Less than half of directors are independent

Chunghwa Chemical Synthesis & Biotech Co., Ltd., Annual General Meeting, May 25, 2022

Recent updates

Why Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Shaky Earnings Are Just The Beginning Of Its Problems

Third quarter 2024 earnings released: NT$0.11 loss per share (vs NT$0.15 profit in 3Q 2023)

Chunghwa Chemical Synthesis & Biotech (TWSE:1762) Has A Somewhat Strained Balance Sheet

New minor risk - Market cap size

Chunghwa Chemical Synthesis & Biotech Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024

New minor risk - Market cap size

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Dividend sustainability

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry

Chunghwa Chemical Synthesis & Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80

Dividend reduced to NT$0.80

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Elects Hou-Kai as Vice Chairman

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Chunghwa Chemical Synthesis & Biotech Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2023 earnings: EPS and revenues miss analyst expectations

Chunghwa Chemical Synthesis & Biotech Co., Ltd., Annual General Meeting, May 30, 2024

Insufficient new directors

New minor risk - Profit margin trend

Second quarter 2023 earnings: Revenues in line with analyst expectations

Upcoming dividend of NT$1.30 per share at 1.6% yield

Investor sentiment deteriorates as stock falls 16%

Now 26% undervalued after recent price drop

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Cash Dividend for the Year 2022

Now 26% undervalued

Investor sentiment improves as stock rises 15%

Price target increased by 12% to NT$91.50

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to NT$91.40

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$1.30 per share

Now 20% undervalued after recent price drop

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Dividend, Payable on August 18, 2022

Price target decreased to NT$84.63

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces Appointment of Kuan Arthur¡G as Independent Director

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Chunghwa Chemical Synthesis & Biotech Co., Ltd., Annual General Meeting, May 25, 2022

Price target increased to NT$103

Third quarter 2021 earnings released: EPS NT$1.09 (vs NT$0.44 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS NT$1.63 (vs NT$4.79 in 2Q 2020)

Upcoming dividend of NT$1.50 per share

First quarter 2021 earnings released: EPS NT$1.27 (vs NT$0.36 in 1Q 2020)

Full year 2020 earnings released: EPS NT$6.86 (vs NT$1.51 in FY 2019)

A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Chunghwa Chemical Synthesis & Biotech Co., Ltd., Annual General Meeting, May 24, 2021

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend

New 90-day low: NT$59.10

Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?

New 90-day low: NT$60.80

The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It

Third quarter 2020 earnings released: EPS NT$0.44

Revenue and earnings miss expectations

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Announces the Change of Representative of the Company's Legal Person Director

New 90-day high: NT$75.30

New 90-day high - NT$66.50

First half earnings released

Upcoming Dividend of NT$0.80 Per Share

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri